Abstract:

Objective  To monitor gastroesophageal reflux disease(GERD) in infants less than 3 months of age by 24-hour esophageal pH to improve its accuracy,and to relieve clinical symptoms of GERD by administering oral mosapride to children with GERD.

Methods   For 49 children with suspected GERD(<3 months of age), 24-hour esophageal pH monitoring was used to monitor its characteristics, and children with GERD were orally administered with mosapride to evaluate its efficacy.

Results   Of 49 children with suspected GERD, 33 were eligible for GERD, accounting for 67.3%; among children with GERD, 23 of them were neonates, which was significantly higher than that of non-neonates(P＜0.05).The clinical manifestations of GERD were vomiting, accounting for 88.2%, and coughing, accounting for 41.2%. The frequency of acid exposure and duration of continuous acid exposure in infants with neonatal GERD increased as compared with non-neonates(P＜0.05). Compared with GER-negative patients, mosapride had a significant effect on GER-positive children. The effective rate, serum gastrin and plasma motilin levels in GER-positive children were significantly higher than those in GER-negative children(P＜0.05), while the incidence of vomiting in GER-positive children was significantly lower than that in GER-negative children(P＜0.05).

Conclusion  24-hour esophageal dynamic pH monitoring technology is still an accurate method for the diagnosis of GERD in infants. Mosapride has an obvious therapeutic effect on GERD of infants, which can promote the development and recovery of early growth and development of infants.

Key words: gastroesophageal reflux, hydrogen-ion concentration, mosapride